agilon health, inc. provides healthcare services for seniors through primary care physicians in communities across the United States. It offers a platform that manages patients' total healthcare needs on a subscription-like per-member, per-month basis. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. Founded in 2016, it is based in Westerville, Ohio.
Outpatient and Specialty Care Stocks Post Strong Q2 Results
Outpatient and specialty care stocks tracked by the publication reported strong second-quarter results, with revenues beating analysts' consensus estimates by 2.6% and next quarter's revenue guidance coming in 3.3% above expectations. U.S. Physical Therapy reported revenues of $214.1 million, up 8.5% year on year, exceeding expectations by 1.9% but missing EPS estimates significantly. LifeStance Health Group delivered the biggest analyst estimate beat, fastest revenue growth, and highest full-year guidance raise in the group, with revenues of $435.4 million, up 26.1% year on year. DaVita reported revenues of $3.55 billion, up 5.2% year on year, but missed full-year EPS guidance estimates and delivered the weakest performance against analyst estimates among its peers. Surgery Partners reported revenues of $848.9 million, up 2.7% year on year, beating expectations by 2.2%, while agilon health reported revenues of $1.49 billion, up 7.2% year on year, surpassing expectations by 2.8% and delivering the highest guidance raise in the group.
Agilon Health swings to Q2 profit, lifts 2026 revenue outlook
Agilon Health swung to a net profit in the second quarter of 2026 and raised its full-year revenue forecast. The company reported net income of $17.76 million, or $1.07 per share, compared with a net loss of $104.37 million, or $6.31 per share, a year earlier. Revenue rose to $1.49 billion from $1.39 billion. For the third quarter, Agilon expects revenue between $1.44 billion and $1.47 billion, and it lifted its full-year 2026 revenue guidance to a range of $5.77 billion to $5.86 billion, up from the prior outlook of $5.68 billion to $5.80 billion. Total members on the Agilon platform stood at 549,000 as of June 30, 2026, including 437,000 Medicare Advantage members and 112,000 ACO model beneficiaries. The stock gained 13.79% in regular trading to close at $107.85 and rose a further 3.85% in overnight trading to $112.
Outpatient and specialty care stocks rise 62.3% on average after strong Q1 earnings
The six outpatient and specialty care stocks tracked by this publication reported a strong first quarter, with revenues beating analysts' consensus estimates by 2% and next quarter's revenue guidance coming in 5.9% above expectations. Encompass Health reported revenues of 1.59 billion dollars, up 9% year on year and exceeding estimates by 1.2%, while agilon health posted revenues of 1.42 billion dollars, down 7.3% year on year but beating estimates by 3.2% and delivering the highest guidance raise among its peers. U.S. Physical Therapy, the weakest performer, reported revenues of 198.3 million dollars, up 7.9% year on year and in line with expectations, but significantly missed analysts' EPS estimates. LifeStance Health Group recorded revenues of 403.5 million dollars, up 21.2% year on year and topping estimates by 4.2%, achieving the fastest revenue growth and biggest analyst estimate beat in the group. DaVita reported revenues of 3.42 billion dollars, up 6% year on year and surpassing estimates by 2.1%, with a beat on both EPS and full-year EPS guidance. Since their latest earnings results, share prices of these outpatient and specialty care stocks have risen 62.3% on average.
Biotech Stocks CareDx, Integra, Agilon, Bioventus, Enliven Hit 52-Week Highs
Several biotech stocks reached 52-week highs on July 16, 2026, driven by upcoming quarterly reports and conference participation. CareDx saw its stock hit a 52-week high of 40.38%, rising over 25% intraday, after announcing Medicare coverage for its AlloSure, AlloMap, and AlloSeq transplant rejection tests and reporting a 39% first-quarter revenue increase to $118 million. Integra LifeSciences shares rose over 5% to a 52-week high of $20.26, supported by recent product approvals and first-quarter revenue of $391.9 million. Agilon Health, which serves over 536,000 senior members through its subscription platform, expects full-year 2026 revenue of $5.68 billion. Bioventus touched a 52-week high of $12.53, rising over 3%, with first-quarter revenue up 7% to $132 million. Enliven Therapeutics shares rose over 6% to a 52-week high of $53.89 following encouraging interim data for its leukemia drug candidate and a recent public offering that raised about $460 million.
agilon health flagged as risky with declining customers and cash burn
agilon health's stock has surged 538% in six months to a 52-week high of $117.62, but analysts highlight three risks. Its customer base fell to 426,000, averaging a 3.1% annual decline over two years, signaling competitive or saturation pressures. Revenue growth is expected to stall in the next 12 months, a sharp slowdown from 34.1% annualized growth over the past five years. The company has burned cash over the long term, with a five-year average free cash flow margin of negative 2.8%, meaning it lost $2.76 for every $100 in revenue. The stock trades at 97.9 times forward EV-to-EBITDA, and analysts suggest a digital advertising pick as a better alternative.
Three Healthcare Stocks with Questionable Fundamentals
Three healthcare stocks may face trouble due to weak fundamentals. Danaher has seen no organic revenue growth over the past two years, its operating margin fell by 10.6 percentage points over five years, and earnings per share were flat. Solventum's organic revenue growth fell short of benchmarks, sales are projected to be flat over the next 12 months, and its free cash flow margin dropped by 30.8 percentage points over five years. agilon health experienced underwhelming customer growth, flat revenue is expected over the next 12 months, and the company has cash-burning tendencies.
Surgery Partners Q1 revenue beats estimates but issues weakest full-year guidance among peers
Surgery Partners reported first-quarter revenues of $810.9 million, up 4.5% year on year and exceeding analyst expectations by 1.6%, while also beating earnings per share estimates. However, the company delivered the weakest full-year guidance update among the seven outpatient and specialty care stocks tracked, a group that collectively beat revenue consensus by 1.9% and saw next-quarter guidance come in 5.9% above expectations. Shares of Surgery Partners have risen 2.5% since the report to $14.56. The broader peer group has averaged a 50.3% share price gain since their latest earnings, with agilon health surging 309% after posting the highest guidance raise, while U.S. Physical Therapy fell 14% after the weakest performance against analyst estimates.
United States